ASCO
Refine Search
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Biotechnology
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2024
Biotechnology
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strength of its cancer medicines with its latest data. 3 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Pharmaceutical
Eli Lilly has released updated data from its Phase I/II clinical trial evaluating olomorasib. 3 June 2024
Pharmaceutical
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
Biotechnology
US biotechs Gilead Sciences and Arcus Biosciences on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study. 3 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction. 3 June 2024
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics presented updated exploratory subgroup analyses from the Phase III SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the American Society of Clinical Oncology (ASCO). 2 June 2024
Biotechnology
US healthcare giant Johnson & Johnson (NYSE: JNJ) released new data from the Phase III MARIPOSA study demonstrating the efficacy of first-line treatment with Rybrevant (amivantamab) in combination with lazertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. 1 June 2024
ASCO 2024
]S pharma giant Pfizer was trading more than 1% higher during Friday morning’s New York activity. 31 May 2024
Biotechnology
With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they intend to present. 29 May 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
Swiss cancer giant Novartis and German drugmaker Bayer are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024. 17 May 2024
Biotechnology
US biotech major Gilead Sciences has announced positive results from the primary analysis of the Phase III TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) versus physicians’ choice of chemotherapy (TPC) in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. 6 June 2022
Biotechnology
Swiss pharma giant Novartis on Friday announced results of an exploratory retrospective biomarker analysis finding that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect treatment benefit with Piqray (alpelisib) plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. 6 June 2022
Biotechnology
New pivotal data is to be presented on Roche’s CD20xCD3 T-cell engaging bispecific antibody, glofitamab at this week’s 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2022 Congress. 30 May 2022
Biotechnology
At the 2022 annual meeting of the American Society of Clinical Oncology (ASCO 22), Shanghai-based cancer company I-Mab is presenting new Phase I data for uliledlimab. 30 May 2022
Biotechnology
A new kind of therapy which raises the prospect of an off-the-shelf approach to CAR T-cell treatment has scored an early-stage win, lifting shares in developer Adicet Bio. 27 May 2022
Biotechnology
Budget medicine specialist EQRx, a company focused on delivering innovative medicines at significantly lower prices, will present new data for its two lead programs at the annual meeting of the American Society of Clinical Oncology (ASCO 22). 27 May 2022
Biotechnology
US biotech major Amgen has promised new data from across its oncology innovative medicines and biosimilars portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting next week. 27 May 2022
Pharmaceutical
The world’s leading cancer conference kicks off in Chicago on Friday June 3, and for many industry participants, it will be the first time they have attended a medical meeting in person since the pandemic started over two years ago. 25 May 2022
Biotechnology
Novartis has shared the highlights of the data it will present at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2022 Hybrid Congress. 13 May 2022
Biotechnology
US pharma giant Merck & Co has announced the final results from the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab) plus best supportive care (BSC) in patients in Asia with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. 19 January 2022
Biotechnology
Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically-significant and clinically-meaningful improvement in overall survival (OS) versus sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. 19 January 2022
Pharmaceutical
The Franco-American pairing of Ipsen and Exelixis have announced detailed results from the Phase III COSMIC-311 pivotal trial of Cabometyx (cabozantinib) in previously-treated radioactive iodine-refractory differentiated thyroid cancer. 9 June 2021
Biotechnology
New research led by the Roswell Park Comprehensive Cancer Center in Buffalo, USA, shows that treatment with checkpoint blockers has led to a significant improvement among people with a certain type of kidney cancer. 8 June 2021
Biotechnology
Chinese biopharma BeiGene has announced data from two pivotal trials of its anti-PD-1 antibody tislelizumab at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021). 7 June 2021
Pharmaceutical
French pharma major Sanofi presented new data for its oral selective estrogen receptor degrader (SERD), amcenestrant, in combination with Ibrance (CDK4/6 inhibitor), at this year’s meeting of the American Society for Clinical Oncology (ASCO). 7 June 2021
Biotechnology
At the annual meeting of the American Society of Clinical Oncology, Gilead Sciences subsidiary Kite has presented encouraging data from a primary analysis of the Phase I/II ZUMA-3 trial. 7 June 2021
Biotechnology
Swiss pharma giant Roche today announced new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) that are being presented at the 2021 ASCO Annual Meeting. 4 June 2021
Pharmaceutical
AstraZeneca and Merck & Co’s Lynparza (olaparib) has become the first drug targeting BRCA mutations to show clinical benefit in the adjuvant setting. 4 June 2021
Biotechnology
China’s Shanghai Junshi Biosciences and US biosimilars company Coherus BioSciences have released positive results from the pivotal study JUPITER-02, a randomized, double-blind, placebo-controlled Phase III clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). 4 June 2021
Biotechnology
Swiss pharms giant Novartis has announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated significant improvement in overall survival (OS) compared to SOC alone, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). 4 June 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze